Clinical Trial

Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-08-08; most recent amendment 2026-05-06.
Status change: Recruiting → Active, Not Recruiting 2024-11-04
Trial Details
NCT Number NCT06550128
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions Hepatitis B, Chronic
Enrollment 86 participants
Start Date 2024-07-10
Primary Completion 2025-05-26 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29